Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

In the past two years, due to the strong cash flow driven by COVID-19, the industrial parks of Chinese IVD enterprises have been ready to land.

Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.

An analysis of monkeypox virus (MPXV) genomes from the ongoing global outbreak has found that the samples cluster together, indicating a single origin for them.

Recently, Shenzhen Eurekabio Technology Co., Ltd. (hereinafter referred to as "Eurekabio") announced that it had completed the 100 million CNY of round B financing.

Israeli diagnostics firm Nucleix said on Wednesday that it has expanded the European Union label indication of its Bladder EpiCheck urothelial cancer test.

Fujirebio announced on Thursday that it is acquiring neurodegenerative disease diagnostic company ADx NeuroSciences for €40 million ($42.1 million).

On May 20, the customs statistical data platform updated the import and export data. The export value of China’s COVID-19 reagents in May was 1.394 billion yuan, which is less than 10% of the value in January.

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

Belgian molecular diagnostics firm Biocartis said on Wednesday that it will develop a molecular test to identify patients with non-small cell lung cancer most likely to respond to AstraZeneca's Tagrisso (osimertinib) treatment.

On June 22, China IPO learned that Mega Genomics (06667.HK) was officially listed on Hong Kong Exchanges and Clearing Limited today.